<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Gabapentin enacarbil: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Gabapentin enacarbil: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Gabapentin enacarbil: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="16487" href="/d/html/16487.html" rel="external">see "Gabapentin enacarbil: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F12924419"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Horizant</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F12732347"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antiseizure Agent, Miscellaneous</li></ul></div>
<div class="block doa drugH1Div" id="F12805677"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> For patients with respiratory disease, initiate therapy at the lowest dose (FDA 2019). Gabapentin enacarbil is not interchangeable with other gabapentin products due to differing pharmacokinetic profiles.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="cd263141-59d9-4f4b-8e26-25d16a66c401">Postherpetic neuralgia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Postherpetic neuralgia:</b>
<b>Oral:</b> Initial: 600 mg once daily in the morning for 3 days, then increase to 600 mg twice daily; increasing to &gt;1.2 g/day may provide no additional benefit and increase side effects.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="8f697f01-66fe-41f3-8c4d-7ff9a727a5e7">Restless legs syndrome</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Restless legs syndrome:</b>
<b>Oral:</b> 300 to 600 mg once daily at ~5:00 pm (AAN [Winkelman 2016]; Silber 2021).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Discontinuation of therapy:</b> The manufacturer recommends a taper when discontinuing to decrease risk of withdrawal seizure:</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Twice-daily administration:</b> Reduce dose to once daily for 1 week prior to discontinuation.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Once-daily administration, dose &gt;600 mg/day:</b> Reduce dose to 600 mg once daily for 1 week.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Once-daily administration, dose ≤600 mg/day:</b> May discontinue without taper.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991890"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Estimation of kidney function for the purpose of drug dosing should be done using the Cockcroft-Gault formula.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Postherpetic neuralgia:</b></p>
<p style="text-indent:-2em;margin-left:4em;">CrCl ≥60 mL/minute: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl 30 to 59 mL/minute: <b>Oral: </b>Initial: 300 mg every morning for 3 days, then increase to 300 mg twice daily. May increase to 600 mg twice daily as needed based on tolerability and efficacy. When discontinuing, reduce current dose to once daily in the morning for 1 week.</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl 15 to 29 mL/minute: <b>Oral: </b>Initial: 300 mg in the morning on day 1 and on day 3; then increase to 300 mg once daily. May increase to 300 mg twice daily if needed based on tolerability and efficacy. When discontinuing, if current dose is 300 mg twice daily, reduce to 300 mg once daily for 1 week. If current dose is 300 mg once daily, no taper is needed.</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl &lt;15 mL/minute (not on hemodialysis): <b>Oral: </b>Initial: 300 mg every other day in the morning; may increase dose to 300 mg once daily if needed based on tolerability and efficacy. When discontinuing, no taper is needed.</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl &lt;15 mL/minute on hemodialysis, intermittent (thrice weekly): Dialyzable (~29%): <b>Oral: </b>Initial: 300 mg following every dialysis. May increase to 600 mg following every dialysis if needed based on tolerability and efficacy. When discontinuing, no taper is needed.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Restless legs syndrome:</b></p>
<p style="text-indent:-2em;margin-left:4em;">CrCl ≥60 mL/minute: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl 30 to 59 mL/minute: <b>Oral: </b>Initial: 300 mg once daily; increase to 600 mg once daily as needed.</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl 15 to 29 mL/minute: <b>Oral: </b>300 mg once daily.</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl &lt;15 mL/minute (not on hemodialysis): <b>Oral:</b> 300 mg every other day.</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl &lt;15 mL/minute on hemodialysis, intermittent (thrice weekly): Use is not recommended.</p></div>
<div class="block doha drugH1Div" id="F50988803"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">No dosage adjustment provided in manufacturer’s labeling.</p></div>
<div class="block doe drugH1Div" id="F12805678"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Initiate therapy at the lowest dose (FDA 2019). Refer to adult dosing. <b>Note:</b> A starting dose of 300 mg once daily for the treatment of restless leg syndrome in patients &gt;65 years of age has been recommended (Garcia-Borreguero 2016).</p></div>
<div class="block adr drugH1Div" id="F12805161"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Percentages reported are for restless leg syndrome (RLS) 600 mg daily and postherpetic neuralgia (PHN) 1200 mg daily.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%: Nervous system: Dizziness (13% to 17%), drowsiness (RLS: ≤20%; PHN: ≤10%), headache (10% to 12%), sedated state (RLS: ≤20%; PHN: ≤10%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Peripheral edema (6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Weight gain (3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Flatulence (≤3%), increased appetite (≤2%), nausea (6% to 8%), xerostomia (≤3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Balance impairment (&lt;2%), depression (&lt;2%), disorientation (&lt;2%), fatigue (≤6%), insomnia (PHN: 3%), intoxicated feeling (&lt;2%), irritability (≤4%), lethargy (&lt;2%), vertigo (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Asthenia (≤6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Blurred vision (≤2%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%, postmarketing, and/or case reports: Breast hypertrophy (gabapentin), bullous pemphigoid (gabapentin), decreased libido, drug reaction with eosinophilia and systemic symptoms (gabapentin), feeling abnormal, gynecomastia (gabapentin), increased creatine phosphokinase in blood specimen (gabapentin), respiratory depression (FDA Safety Alert, December 19, 2019), suicidal ideation (gabapentin), suicidal tendencies (gabapentin)</p></div>
<div class="block coi drugH1Div" id="F12805155"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">There are no contraindications listed within the manufacturer’s labeling.</p></div>
<div class="block war drugH1Div" id="F12805156"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks that require mental alertness (eg, operating machinery, driving).</p>
<p style="text-indent:-2em;margin-left:4em;">• Multiorgan hypersensitivity: Potentially serious, sometimes fatal multiorgan hypersensitivity (also known as drug reaction with eosinophilia and systemic symptoms) has been reported with some antiseizure drugs, including gabapentin. Monitor for signs and symptoms of possible disparate manifestations associated with lymphatic, hepatic, renal, cardiac, and/or hematologic systems; fever, rash, and eosinophilia may also be present. Discontinue immediately if suspected.</p>
<p style="text-indent:-2em;margin-left:4em;">• Respiratory effects: Serious, life-threatening, and fatal respiratory depression may occur in patients taking gabapentin enacarbil; risk may be increased with conditions such as chronic obstructive pulmonary disease, in older adults, and with the concomitant use of opioids and other CNS depressants. Initiate at the lowest dose and monitor patients for symptoms of respiratory depression and sedation in patients with underlying respiratory disease (FDA 2019; Mattson 2022).</p>
<p style="text-indent:-2em;margin-left:4em;">• Suicidal ideation: Pooled analysis of trials involving gabapentin and other antiseizure medications (regardless of indication) showed an increased risk of suicidal thoughts/behavior (incidence rate: 0.43% treated patients compared to 0.24% of patients receiving placebo); risk observed as early as 1 week after initiation and continued through duration of trials (most trials ≤24 weeks). Gabapentin enacarbil is a prodrug of gabapentin and may also increase patient's risk. Monitor all patients for notable changes in behavior that might indicate suicidal thoughts or depression; notify health care provider immediately if symptoms occur.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Myasthenia gravis: Use with caution in patients with myasthenia gravis; may exacerbate condition (Mehrizi 2012).</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with renal impairment; dose adjustment is needed.</p>
<p style="text-indent:-2em;margin-left:4em;">• Respiratory disease: Gabapentin enacarbil may cause respiratory depression; use caution and initiate with the lowest recommended dose in patients with respiratory compromise (FDA 2019).</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Special populations:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Older adults: Gabapentin may cause respiratory depression; use caution and initiate with the lowest recommended dose in older adults (FDA 2019).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Restless legs syndrome: Not recommended for use in patients who are required to sleep during the day and remain awake during the night.</p>
<p style="text-indent:-2em;margin-left:4em;">• Discontinuation of therapy: To avoid the potential for withdrawal seizure, dose reduction is recommended for patients with postherpetic neuralgia receiving twice daily doses or patients with restless legs syndrome (RLS) receiving daily doses &gt;600 mg (daily doses of ≤600 mg can be discontinued without tapering in patients with RLS).</p>
<p style="text-indent:-2em;margin-left:4em;">• Product interchangeability: Gabapentin enacarbil (Horizant) and other gabapentin products are not interchangeable due to differences in formulation, indications, and pharmacokinetics.</p>
<p style="text-indent:-2em;margin-left:4em;">• Tumorigenic potential: Rat studies demonstrated an association with pancreatic adenocarcinoma (clinical implication unknown).</p></div>
<div class="block foc drugH1Div" id="F12924420"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Extended Release, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Horizant: 300 mg, 600 mg</p></div>
<div class="block geq drugH1Div" id="F12805149"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F16322897"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablet, controlled release</b> (Horizant Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">300 mg (per each): $20.63</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">600 mg (per each): $20.63</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block adm drugH1Div" id="F12805685"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral:</b> Tablet should be swallowed whole; do not break, chew, cut, or crush. Administer with food.</p>
<p style="text-indent:-2em;margin-left:2em;">Restless legs syndrome: Administer at ~5:00 pm daily.</p></div>
<div class="block meg drugH1Div" id="F12805146"><span class="drugH1">Medication Guide and/or Vaccine Information Statement (VIS)</span>
<p style="text-indent:0em;display:inline">An FDA-approved patient medication guide, which is available with the product information and at <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2020%2F022399s010lbl.pdf%23page%3D27&amp;token=bz1sLVyDTfYqcPHmxnc5bbeNJQeyCfFb8x3Tp9j%2BELUXogTrf7hxOMqGY%2F3koUBwbJ1NisBePdulK%2BOoh4vhR9YYw%2FsAGB8Mc49br88Da55Kdf2qfAcrOpUrQqoPPHd6&amp;TOPIC_ID=16486" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022399s010lbl.pdf#page=27</a>, must be dispensed with this medication.</p></div>
<div class="block use drugH1Div" id="F12732261"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Postherpetic neuralgia: </b>Management of postherpetic neuralgia.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Restless legs syndrome: </b>Treatment of moderate to severe restless legs syndrome.</p></div>
<div class="block mst drugH1Div" id="F53013582"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Gabapentin enacarbil may be confused with gabapentin, gemfibrozil</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">The Institute for Safe Medication Practices (ISMP) includes this medication (when used for neuropathic pain) among its list of drugs that have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299374"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of OCT2</p></div>
<div class="block dri drugH1Div" id="F12817729"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Alcohol (Ethyl): May enhance the CNS depressant effect of Gabapentin Enacarbil. Alcohol (Ethyl) may increase the absorption of Gabapentin Enacarbil. Specifically, the rate of absorption may be enhanced, as alcohol may speed the release of drug from the extended-release tablet.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alizapride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Azelastine (Nasal): May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Blonanserin: CNS Depressants may enhance the CNS depressant effect of Blonanserin.  Management: Use caution if coadministering blonanserin and CNS depressants; dose reduction of the other CNS depressant may be required. Strong CNS depressants should not be coadministered with blonanserin.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brexanolone: CNS Depressants may enhance the CNS depressant effect of Brexanolone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brimonidine (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromopride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromperidol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of other CNS depressants, and avoiding such drugs in patients at high risk of buprenorphine overuse/self-injection. Initiate buprenorphine at lower doses in patients already receiving CNS depressants.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cannabinoid-Containing Products: CNS Depressants may enhance the CNS depressant effect of Cannabinoid-Containing Products. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chlormethiazole: May enhance the CNS depressant effect of CNS Depressants. Management: Monitor closely for evidence of excessive CNS depression. The chlormethiazole labeling states that an appropriately reduced dose should be used if such a combination must be used.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chlorphenesin Carbamate: May enhance the adverse/toxic effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Daridorexant: May enhance the CNS depressant effect of CNS Depressants. Management: Dose reduction of daridorexant and/or any other CNS depressant may be necessary. Use of daridorexant with alcohol is not recommended, and the use of daridorexant with any other drug to treat insomnia is not recommended.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">DexmedeTOMIDine: CNS Depressants may enhance the CNS depressant effect of DexmedeTOMIDine.  Management: Monitor for increased CNS depression during coadministration of dexmedetomidine and CNS depressants, and consider dose reductions of either agent to avoid excessive CNS depression.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Difelikefalin: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dimethindene (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Doxylamine: CNS Depressants may enhance the CNS depressant effect of Doxylamine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DroPERidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (eg, opioids, barbiturates) with concomitant use.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Esketamine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flunarizine: CNS Depressants may enhance the CNS depressant effect of Flunarizine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flunitrazepam: CNS Depressants may enhance the CNS depressant effect of Flunitrazepam.  Management: Reduce the dose of CNS depressants when combined with flunitrazepam and monitor patients for evidence of CNS depression (eg, sedation, respiratory depression). Use non-CNS depressant alternatives when available.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants. Management: Consider a decrease in the CNS depressant dose, as appropriate, when used together with hydroxyzine. Increase monitoring of signs/symptoms of CNS depression in any patient receiving hydroxyzine together with another CNS depressant.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ixabepilone: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Kava Kava: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Kratom: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lemborexant: May enhance the CNS depressant effect of CNS Depressants. Management: Dosage adjustments of lemborexant and of concomitant CNS depressants may be necessary when administered together because of potentially additive CNS depressant effects. Close monitoring for CNS depressant effects is necessary.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lisuride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lofexidine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce the usual dose of CNS depressants by 50% if starting methotrimeprazine until the dose of methotrimeprazine is stable. Monitor patient closely for evidence of CNS depression.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Metoclopramide: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">MetyroSINE: CNS Depressants may enhance the sedative effect of MetyroSINE. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Minocycline (Systemic): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nabilone: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olopatadine (Nasal): May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Opioid Agonists: CNS Depressants may enhance the CNS depressant effect of Opioid Agonists.  Management: Avoid concomitant use of opioid agonists and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Orphenadrine: CNS Depressants may enhance the CNS depressant effect of Orphenadrine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oxomemazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oxybate Salt Products: CNS Depressants may enhance the CNS depressant effect of Oxybate Salt Products.  Management: Consider alternatives to this combination when possible. If combined, dose reduction or discontinuation of one or more CNS depressants (including the oxybate salt product) should be considered. Interrupt oxybate salt treatment during short-term opioid use<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">OxyCODONE: CNS Depressants may enhance the CNS depressant effect of OxyCODONE.  Management: Avoid concomitant use of oxycodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Perampanel: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Piribedil: CNS Depressants may enhance the CNS depressant effect of Piribedil. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Procarbazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ropeginterferon Alfa-2b: CNS Depressants may enhance the adverse/toxic effect of Ropeginterferon Alfa-2b. Specifically, the risk of neuropsychiatric adverse effects may be increased.  Management: Avoid coadministration of ropeginterferon alfa-2b and other CNS depressants. If this combination cannot be avoided, monitor patients for neuropsychiatric adverse effects (eg, depression, suicidal ideation, aggression, mania).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rufinamide: May enhance the adverse/toxic effect of CNS Depressants. Specifically, sleepiness and dizziness may be enhanced.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Suvorexant: CNS Depressants may enhance the CNS depressant effect of Suvorexant.  Management: Dose reduction of suvorexant and/or any other CNS depressant may be necessary.  Use of suvorexant with alcohol is not recommended, and the use of suvorexant with any other drug to treat insomnia is not recommended.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thalidomide: CNS Depressants may enhance the CNS depressant effect of Thalidomide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Trimeprazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Valerian: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem adult dose to 1.75 mg for  men who are also receiving other CNS depressants. No such dose change is recommended for women. Avoid use with other CNS depressants at bedtime; avoid use with alcohol.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zuranolone: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to the use of zuranolone with other CNS depressants or alcohol. If combined, consider a zuranolone dose reduction and monitor patients closely for increased CNS depressant effects.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block foi drugH1Div" id="F12805662"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;display:inline">Ethanol may cause rapid release of gabapentin enacarbil from the extended release tablet.  Management: Avoid ethanol. </p></div>
<div class="block pri drugH1Div" id="F12805152"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Gabapentin enacarbil is the prodrug of gabapentin; bioavailability following gabapentin enacarbil is increased in comparison to gabapentin (Backonja 2011). Current guidelines note there is insufficient evidence to recommend gabapentin enacarbil in pregnant women for the treatment of restless legs syndrome (Picchietti 2015); use should be avoided (Garcia-Borreguero 2016).</p>
<p style="text-indent:0em;margin-top:2em;">Refer to Gabapentin monograph for information related to gabapentin exposure during pregnancy.</p></div>
<div class="block brc drugH1Div" id="F12805154"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:0em;display:inline">It is not known if gabapentin is present in breast milk following maternal use of gabapentin enacarbil; however, gabapentin is present in breast milk following administration of other dosage forms.</p>
<p style="text-indent:0em;margin-top:2em;">According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and the benefits of treatment to the mother. Current guidelines note there is insufficient evidence to recommend gabapentin enacarbil in breastfeeding women for the treatment of restless legs syndrome (Picchietti 2015).</p>
<p style="text-indent:0em;margin-top:2em;">Refer to Gabapentin monograph for additional information related to gabapentin exposure in breastfeeding women.</p></div>
<div class="block dic drugH1Div" id="F12805684"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Take with food.</p></div>
<div class="block mop drugH1Div" id="F12805687"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Renal function (baseline and as clinically indicated); suicidality (eg, suicidal thoughts, depression, behavioral changes)</p></div>
<div class="block pha drugH1Div" id="F12805665"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Gabapentin enacarbil is a prodrug of gabapentin. Gabapentin is structurally related to GABA. However, it does not bind to GABA<sub>A</sub> or GABA<sub>B</sub> receptors, and it does not appear to influence degradation or uptake of GABA. High affinity gabapentin binding sites have been located throughout the brain; these sites correspond to the presence of voltage-gated calcium channels specifically possessing the alpha-2-delta-1 subunit. This channel appears to be located presynaptically, and may modulate the release of excitatory neurotransmitters. These effects on restless legs syndrome are unknown.</p></div>
<div class="block phk drugH1Div" id="F12805667"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Mediated by active transport via proton-linked monocarboxylate transporter, MCT-1</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: 76 L </p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: &lt;3% </p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: With food: ~75%; Fasting: 42% to 65% </p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Prodrug hydrolyzed primarily in the intestines to gabapentin (active metabolite)</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, plasma: With food: 7.3 hours; Fasting: 5 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: 5-6 hours </p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (94%); feces (5%)</p></div>
<div class="block phksp drugH1Div" id="F51196080"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: In moderate and severe renal impairment, clearance was decreased to 3 and 1 L/hour, respectively, compared with 5-7 L/hour in nonrenal impairment patients.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F49939690"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Regnite</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-21627766">
<a name="21627766"></a>Backonja MM, Canafax DM, and Cundy KC, "Efficacy of Gabapentin Enacarbil vs Placebo in Patients With Postherpetic Neuralgia and a Pharmacokinetic Comparison With Oral Gabapentin," <i>Pain Med</i>, 2011, 12(7):1098-108.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gabapentin-enacarbil-drug-information/abstract-text/21627766/pubmed" id="21627766" target="_blank">21627766</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27448465">
<a name="27448465"></a>Garcia-Borreguero D, Silber MH, Winkelman JW, et al. Guidelines for the first-line treatment of restless legs syndrome/Willis-Ekbom disease, prevention and treatment of dopaminergic augmentation: a combined task force of the IRLSSG, EURLSSG, and the RLS-foundation. <i>Sleep Med</i>. 2016;21:1-11. doi: 10.1016/j.sleep.2016.01.017.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gabapentin-enacarbil-drug-information/abstract-text/27448465/pubmed" id="27448465" target="_blank">27448465</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Horizant (gabapentin enacarbil) [prescribing information]. Atlanta, GA: Arbor Pharmaceuticals LLC; April 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35552367">
<a name="35552367"></a>Mattson CL, Chowdhury F, Gilson TP. Notes from the field: trends in gabapentin detection and involvement in drug overdose deaths - 23 states and the District of Columbia, 2019-2020. <i>MMWR Morb Mortal Wkly Rep</i>. 2022;71(19):664-666. doi:10.15585/mmwr.mm7119a3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gabapentin-enacarbil-drug-information/abstract-text/35552367/pubmed" id="35552367" target="_blank">35552367</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Mehrizi M, Fontem RF, Gearhart TR, Pascuzzi RM. Medications and myasthenia gravis (a reference for health care professionals). Indianapolis, In: Indiana University School of Medicine (Department of Neurology); 2012. https://www.myasthenia.org/portals/0/draft_medications_and_myasthenia_gravis_for_MGFA_website_8%2010%2012.pdf. Accessed July 31, 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25553600">
<a name="25553600"></a>Picchietti DL, Hensley JG, Bainbridge JL, et al. Consensus clinical practice guidelines for the diagnosis and treatment of restless legs syndrome/Willis-Ekbom disease during pregnancy and lactation. <i>Sleep Med Rev</i>. 2015;22:64-77.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gabapentin-enacarbil-drug-information/abstract-text/25553600/pubmed" id="25553600" target="_blank">25553600</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Silber MH. Treatment of restless legs syndrome and periodic limb movement disorder in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed September 16, 2021.</div>
</li>
<li>
<div class="reference">
                  US Food and Drug Administration (FDA). FDA Drug Safety Communication. MedWatch. FDA warns about serious breathing problems with seizure and nerve pain medicines gabapentin (Neurontin, Gralise, Horizant) and pregabalin (Lyrica, Lyrica CR). <a href="https://www.fda.gov/drugs/drug-safety-and-availability/fda-warns-about-serious-breathing-problems-seizure-and-nerve-pain-medicines-gabapentin-neurontin" target="_blank">https://www.fda.gov/drugs/drug-safety-and-availability/fda-warns-about-serious-breathing-problems-seizure-and-nerve-pain-medicines-gabapentin-neurontin</a>. Published December 19, 2019. Accessed April 3, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27856776">
<a name="27856776"></a>Winkelman JW, Armstrong MJ, Allen RP, et al. Practice guideline summary: treatment of restless legs syndrome in adults: report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. <i>Neurology</i>. 2016;87(24):2585-2593. doi:10.1212/WNL.0000000000003388<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gabapentin-enacarbil-drug-information/abstract-text/27856776/pubmed" id="27856776" target="_blank">27856776</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 16486 Version 245.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
